End­points Man­u­fac­tur­ing: Charles Riv­er makes a splash for cell and gene ther­a­py spe­cial­ist; 5 ques­tions with Ho­mol­o­gy Med­i­cines

Af­ter a blis­ter­ing start to 2021, it seemed as though news in the biotech man­u­fac­tur­ing world had slowed to a more rea­son­able pace in the last few weeks.

Then the news came down Wednes­day of an ex­pen­sive merg­er in one of the fastest-grow­ing man­u­fac­tur­ing are­nas: cell and gene ther­a­peu­tics. And it comes with a $875 mil­lion cash price tag.

Charles Riv­er Lab­o­ra­to­ries, a play­er in the field for 75 years, bought out Cog­nate BioSer­vices, a cell and gene ther­a­py spe­cial­ist with op­er­a­tions in both North Amer­i­ca and Eu­rope. Pitched as an “ex­cep­tion­al strate­gic fit”, Cog­nate’s ser­vices will give Charles Riv­er a boost in so­lid­i­fy­ing its end-to-end man­u­fac­tur­ing ca­pac­i­ties for cell and gene ther­a­pies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.